Overview PK Study of Dapagliflozin in Pediatric Subjects With T2DM Status: Completed Trial end date: 2014-09-01 Target enrollment: Participant gender: Summary The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM) Phase: Phase 1 Details Lead Sponsor: AstraZenecaBristol-Myers SquibbCollaborators: AstraZenecaBristol-Myers SquibbTreatments: Dapagliflozin